Avantor, Inc. (NYSE:AVTR) Receives Average Rating of "Moderate Buy" from Analysts

Avantor, Inc. (NYSE:AVTR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twelve ratings firms that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $25.92.

Several research firms have weighed in on AVTR. Morgan Stanley dropped their price objective on shares of Avantor from $27.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Barclays dropped their price target on shares of Avantor from $26.00 to $23.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th. Robert W. Baird dropped their price target on shares of Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 28th. Stifel Nicolaus dropped their price target on shares of Avantor from $28.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, February 10th. Finally, Wells Fargo & Company dropped their price target on shares of Avantor from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Monday, February 10th.

Institutional Trading of Avantor

Several large investors have recently modified their holdings of AVTR. Creative Planning boosted its holdings in shares of Avantor by 54.0% during the 3rd quarter. Creative Planning now owns 28,136 shares of the company's stock worth $728,000 after buying an additional 9,866 shares during the period. Blue Trust Inc. boosted its holdings in Avantor by 414.5% in the 3rd quarter. Blue Trust Inc. now owns 7,547 shares of the company's stock valued at $195,000 after purchasing an additional 6,080 shares during the period. Veracity Capital LLC boosted its holdings in Avantor by 1.0% in the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company's stock valued at $1,355,000 after purchasing an additional 543 shares during the period. Castleview Partners LLC boosted its holdings in Avantor by 35.6% in the 3rd quarter. Castleview Partners LLC now owns 17,514 shares of the company's stock valued at $453,000 after purchasing an additional 4,599 shares during the period. Finally, Whittier Trust Co. boosted its holdings in Avantor by 4.7% in the 3rd quarter. Whittier Trust Co. now owns 209,036 shares of the company's stock valued at $5,405,000 after purchasing an additional 9,321 shares during the period. 95.08% of the stock is owned by institutional investors.

Avantor Stock Down 1.3 %

Avantor stock traded down $0.24 during trading hours on Friday, hitting $17.87. The company had a trading volume of 3,913,664 shares, compared to its average volume of 5,012,515. The firm has a market capitalization of $12.16 billion, a P/E ratio of 38.84, a price-to-earnings-growth ratio of 3.87 and a beta of 1.28. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The firm's fifty day moving average is $21.44 and its 200-day moving average is $23.20. Avantor has a fifty-two week low of $17.83 and a fifty-two week high of $28.00.

Avantor (NYSE:AVTR - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same period last year, the firm posted $0.22 EPS. On average, research analysts forecast that Avantor will post 0.98 earnings per share for the current year.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.